Rolapitant Dose 1

Phase 2

MERCK (MRK)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Postoperative Nausea and Vomiting

View Full Landscape

Drug Information

Target Indication

Postoperative Nausea and Vomiting

Clinical Trial

NCT00539721

Last updated: 1/21/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA4/19/2017

Varuby

Prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.Varuby is given as part of combination therapy.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

MRK

MERCK

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

MK-8748Phase 3

Diabetic Retinopathy

alendronate with cholecalciferolPhase 3

Osteoporosis

Simvastatin 20 mg dailyPhase 3

Cardiovascular Disease

EpinephrinePhase 3

Malignant Neoplasms of Male Genital Organs

9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)Phase 3

HPV Positive Oropharyngeal Squamous Cell Carcinoma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts